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INTRODUCTION
Eosinophilic esophagitis (EoE) is a chronic immune/allergic 
condition with a multifactorial etiology.1 EoE was first de-
scribed in 1978,2 and pathological entities have been con-
firmed in reports from 1993 to 1994.3,4 The prevalence and inci-
dence of EoE are increasing worldwide. According to a recent 
meta-analysis, the incidence rate was 7.7/100000 person-years 
in adults, with a prevalence of 42.2 cases per 100000 adults.5 
The most important factors in the diagnosis of EoE are clinical 
symptoms and histological findings. Some EoE patients have 
difficulty swallowing, but most show various atypical symp-
toms, such as vomiting and abdominal pain, or no symptoms.6,7 
Histological diagnosis is confirmed when there are more than 
15 eosinophils per high-power field (HPF).8 EoE exhibits vari-
ous endoscopic features, such as linear furrows, exudate, frag-
ile mucosa, edema, rings, and strictures,9 although the report-
ed prevalence of endoscopic features in EoE patients varies 
among in the literature.10,11 Although these endoscopic features 
are important for the diagnosis of EoE, individual features are 
not sensitive or specific enough to support diagnosis. Recently, 
an EoE endoscopic reference score (EREFS) has been used to 
overcome these limitations and to quantify endoscopic fea-
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Purpose: The prevalence and incidence of eosinophilic esophagitis (EoE) are increasing worldwide. Despite increased under-
standing of inflammatory pathogenesis, changes in endoscopic features after treatment of EoE have not been clearly described. 
We aimed to investigate the reversibility of endoscopic features of EoE after treatment.
Materials and Methods: Out of 58 adult subjects who were diagnosed with EoE at the Yonsei University Health System from July 
2006 to August 2019, we recruited 33 subjects (30 males; mean age: 42 years) whose pre-treatment and post-treatment endoscop-
ic images were available. Endoscopic features included both inflammatory and fibrostenotic features. Exudate, edema, furrow, 
and crepe paper-like mucosa were classified as inflammatory features. Ring and stricture were classified as fibrostenotic features. 
We compared changes in endoscopic features after treatment for EoE. 
Results: After treatment, clinical symptoms improved in all patients. The following endoscopic features were observed before 
treatment: furrow (81.8%), edema (90.9%), exudate (42.4%), ring (27.3%), crepe paper-like mucosa (15.2%), and stricture (3.0%). 
Endoscopic remission was achieved in 21 patients (63.6%). Inflammatory features were reversible (72.7%, p<0.001), whereas fibro-
stenotic features were not (10%, p=0.160). Exudate had resolved in 92.9% of patients, edema in 70% and furrow in 88.9%. Ring and 
stricture persisted in almost all of the patients (9/10) who had these endoscopic features before treatment. 
Conclusion: We outlined the reversibility of endoscopic inflammatory features of EoE. Fibrostenotic features were irreversible af-
ter esophageal remodeling in patients with EoE. However, further validation studies with long-term follow-up are needed.
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tures, and good performance has been reported in several 
studies.12,13 Several studies using the scoring system reported 
decreases in scores after EoE treatment, indirectly confirming 
an observed correlation between EoE activity and endoscopic 
features.12,14 However, despite several studies on EoE, the re-
versibility of endoscopic features after treatment has not been 
clearly described. In this study, we aimed to investigate the re-
versibility of endoscopic features of EoE after treatment.
MATERIALS AND METHODS 
Study subjects and methods
We reviewed the records of 58 patients who were diagnosed 
with EoE at two tertiary gastroenterology centers (Gangnam 
Severance Hospital and Severance Hospital, Yonsei Universi-
ty) from July 2006 to August 2019. Baseline characteristics, in-
cluding age, sex, patient’s symptoms, and endoscopic features, 
were identified retrospectively. The cut-off value for confirm-
ing EoE was more than 15 eosinophils per HPF on esophageal 
biopsy. In all, 33 patients with identifiable endoscopic images 
before and after treatment were enrolled in this study. Endos-
copy was performed for various causes, including examina-
tions for gastrointestinal symptoms and screening for malig-
nancy. If EoE was suspected, two to four biopsy samples were 
taken to obtain enough samples. Treatment for EoE comprised 
the use of a proton-pump inhibitor (PPI) or topical steroids 
(fluticasone propionate) for 4–8 weeks. Even after PPI treat-
ment, a topical steroid was used if symptoms persisted. Fluti-
casone was given as two puffs to swallow twice a day. The daily 
dosage of fluticasone was 1000 mcg. Patients were instructed 
to puff the fluticasone into their mouth at the same time with-
out deep inhalation or using spacers. During PPI treatment, pa-
tients did not follow the six-food elimination diet. After treat-
ment, follow-up endoscopy was performed. This study was 
approved by the Institutional Review Board of Gangnam Sever-
ance Hospital (No. 3-2019-0415).
Endoscopic features
Endoscopic images were captured using standard endoscopes 
Fig. 1. Typical endoscopic features of eosinophilic esophagitis. (A) Esophageal rings. (B) Rings and linear furrows, as well as mucosal edema. (C) Linear 
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(GIF-Q260J, GIF-H260, and GIF-H290; Olympus Medical Sys-
tems, Co., Ltd., Tokyo, Japan). All endoscopic features and re-
ports were reviewed to confirm the endoscopic features. 
Endoscopic features of EoE are presented in Fig. 1. Edema was 
defined as congested, granular, or abnormally colored esopha-
geal mucosa with the loss of normal vasculature. Exudate was 
an irregularly distributed white, viscous substance. Furrow re-
ferred to longitudinal grooves or crevices parallel to the esoph-
ageal long axis, also called linear fissures or tram tracks. Crepe 
paper-like mucosa referred to esophageal mucosa that had 
lost elasticity and bleeds easily. Rings referred to a concentric 
corrugated esophagus, also called as felinization, trachealiza-
tion, or corrugation. Stricture was defined as a focal narrow-
ing of the esophagus. Inflammatory features included edema, 
exudate, furrow, and crepe paper-like mucosa. Fibrostenotic 
features consisted of ring and stricture.
The degree of endoscopic features was recorded according 
to the EREFS. Edema, crepe paper-like mucosa, and strictures 
were recorded as absent or present. Mild exudate was defined 
as less than 10% of the entire esophageal mucosa covered with 
exudate and severe exudate as more than 10% coverage. Fur-
rows were classified as mild (furrows without visible depth) or 
severe (furrows with visible depth or mucosal indentation). 
Rings were classified as mild (circumferential ridges), moder-
ate (distinct rings that do not impair passage of a standard en-
doscope), and severe (distinct rings that impair passage of a 
standard endoscope). 
Statistical analysis
Chi-squared test and Fisher’s exact test were used to analyze 
categorical variables, and the Wilcoxon signed rank test was 
used for non-categorical variables. p<0.05 indicated statistical 
significance. All statistical analyses were performed using SPSS 
version 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
The baseline characteristics of EoE patients are shown in Ta-
ble 1. Our study population included 30 male and 3 female 
patients with a median age of 42 years (range, 21–66). Among 
26 symptomatic patients (78.8%), dysphagia was present in 16 
Table 1. Baseline Characteristics of the Study Cohort with Eosinophilic 
Esophagitis 
Characteristics n (%)
Male sex 30 (90.9)
Age (yr) (median, range) 42 (21–66)
Duration of endoscopic surveillance (median, range) 2 (2–12)
Symptoms
Dysphagia 16 (48.4)












PPI only 23 (69.7)
PPI+fluticasone (swallowed) 9 (27.3)
PPI+balloon dilatation 1 (3.0)
PPI, proton-pump inhibitor.
Table 2. Endoscopic Features according to Symptom
Endoscopic features Symptomatic Asymptomatic p value
Inflammatory feature 26 (100) 7 (100) -
Edema 23 (88.5) 7 (100) 0.346
Exudate 11 (42.3) 3 (42.9) 0.427
Furrows 21 (80.8) 6 (85.7) 0.624
Crepe paper-like mucosa 5 (19.2) 0 (0) 0.277
Fibrostenotic feature 9 (34.6) 1 (14.3) 0.294
Rings 8 (30.8) 1 (14.3) 0.365
Strictures 1 (3.8) 0 (0) 0.788
Data are presented as n (%).
Table 3. Endoscopic Features Before and After Treatment of Eosinophilic 
Esophagitis 
Pre-treatment Post-treatment p value
Inflammatory feature 33 (100) 9 (27.3) <0.001
Edema 30 (90.9) 9 (27.3) <0.001
Mild 17� 6�
Severe 13� 3�
Exudate 14 (42.4) 1 (3.0) <0.001
Mild 10� 1�
Severe 4� 0�
Furrows 27 (81.8) 3 (9.1) <0.001
Mild 16� 2�
Severe 11� 1�
Crepe paper-like mucosa 5 (15.2) 2 (6.1)  0.083
Fibrostenotic feature 10 (30.3) 9 (27.3)  0.160




Strictures 1 (3.0) 1 (3.0) -
Inflammatory EREFS 3.2±1.6 0.6±1.0 <0.001
Fibrostenotic EREFS 0.5±0.8 0.5±0.8  0.317
Total EREFS 3.7±1.8 1.7±1.5 <0.001
EREFS, endoscopic reference score.
Data are presented as n (%) or mean±standard deviation.
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(48.4%), heart burn in 6 (18.2%), dyspepsia in 2 (6.1%), and 
reflux in 2 (6.1%). Seven patients (21.2%) were asymptomatic 
and underwent endoscopy for screening and surveillance of 
gastric cancer. Endoscopic features were not correlated with 
the patients’ symptoms (Table 2). All patients initially received 
a standard dose of a PPI. In nine patients, symptoms did not 
improve after 8 weeks of PPI treatment, so they were adminis-
tered topical steroids; one patient with esophageal stricture 
underwent balloon dilatation. 
The endoscopic features are shown in Table 3. All patients 
showed inflammatory features on pre-treatment endoscopy: 
edema was observed in 30 (90.9%), exudate in 14 (42.4%), fur-
row in 27 (81.8%), and crepe paper-like appearance in 5 
(15.2%). Ten patients (30.4%) showed fibrostenotic features in 
the pre-treatment endoscopy: rings were observed in 9 (27.3%), 
and strictures in 1 (3.0%). According to the EREFS, findings of 
exudates and furrows were mild. All inflammatory features 
showed reversibility, regardless of the degree. Almost all rings 
were moderate rings and persisted after treatment. Mild rings 
were observed in two patients, but disappeared after treat-
ment in one patient. All inflammatory features except crepe 
paper-like mucosa had significantly improved after treatment 
(p<0.001), whereas fibrostenotic features did not. The mean 
EREFS of inflammatory features was 3.2. After treatment for 
EoE, inflammatory EREFS decreased to 0.6 (p<0.001). Total 
EREFS values significantly decreased after treatment (p<0.001). 
However, fibrostenotic EREFS did not decrease after treatment 
(p=0.325). Representative cases of reversible endoscopic fea-
tures and irreversible endoscopic features are shown in Figs. 2 
and 3.
DISCUSSION
Since EoE was recognized in a series of cases 20 years ago,3,4 
there has been much research on it.15 Currently, several aspects 
Fig. 2. Representative cases of reversible endoscopic features. (A) Exudate and furrows were identified before treatment in a patient with eosinophil-
ic esophagitis. (B) After 8 weeks of treatment with a proton pump inhibitor, exudate and furrows disappeared. (C) Inflammatory features, including 
mucosal edema, furrows, and exudate, were identified before treatment in a patient with eosinophilic esophagitis. (D) After treatment, the patient’s 
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Fig. 3. Representative cases of irreversible endoscopic features. (A) Exudate, mucosal pale, and stricture of the esophagus were identified before 
treatment. (B) After balloon dilatation (13-mm balloon) and 8 weeks of treatment with a PPI, exudate and mucosal pale disappeared. Stricture had im-
proved, but was still present. (C) Concentric rings were identified before treatment in a patient with eosinophilic esophagitis. (D) After 8 weeks of 
treatment with PPI, the patient’s symptoms had resolved. However, the concentric rings remained. PPI, proton pump inhibitor.
of this disease are being explored, including clinical character-
istics, underlying mechanisms, and effective treatment. The 
endoscopic features of EoE have been reported since early re-
search on this disease.16 However, they were not included in 
the initial diagnostic guidelines because the endoscopic fea-
tures were inconsistent and poorly understood.17,18 However, 
through various studies over the past 20 years, data on endo-
scopic features have accumulated.12,19 Recently, efforts have 
been made to further systematize the endoscopic features of 
EoE, such as the EREFS system.12
In our study, we reviewed the endoscopy results of 33 patients 
before and after EoE treatment. We investigated their clinical 
characteristics, including endoscopic features and treatment 
outcomes. Male sex and middle age predominance were simi-
lar to those reported in previous studies.20 The most common 
symptom was dysphagia, observed in about 50% of the EoE pa-
tients.21 In this study, 48.4% of the patients had dysphagia. Sev-
en asymptomatic patients were diagnosed with typical endo-
scopic features of EoE. These patients underwent endoscopy 
for gastric cancer screening and surveillance. 
In a recent meta-analysis, longitudinal furrows, edema, and 
concentric rings were the most common endoscopic features in 
EoE patients.22 In our study, edema was the most frequently ob-
served finding, and the prevalences of other typical findings, 
such as furrows, exudate, and rings, were similar to those in pre-
vious studies. In previous studies, normal endoscopic findings 
have been reported in 4–20% EoE patients.22-25 Patients with 
normal endoscopic findings were not included in this study. In 
the cohort of our study, some patients had normal endoscopic 
findings at the time of diagnosis, although they were excluded 
from this study because follow-up endoscopy was not per-
formed after treatment. Rings and strictures are common en-
doscopic features in the fibrostenotic phenotype.26 Patients with 
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served in our study. Although observed only in one patient, 
stricture persisted even after balloon dilatation and EoE treat-
ment. After treatment, 82.7% of inflammatory features disap-
peared, whereas almost all fibro-stenotic features remained.
The limitations of our study are as follows: First, this was a 
retrospective study based on previous clinical and endoscopic 
images. We have reviewed all endoscopic images and results, 
but interobserver variations may occur in taking images or re-
cording reports by several endoscopists over a long period of 
research. Second, the number of patients was small, as EoE is a 
rare disease. In addition, a number of patients refused follow-
up endoscopy after their symptoms improved. Third, the inter-
val time of follow-up endoscopy was not consistent. Despite 
these limitations, this is the first study to report on the revers-
ibility of endoscopic features after treatment for EoE in South 
Korea.
In conclusion, we observed the reversibility of endoscopic 
inflammatory features of EoE. Fibrostenotic features were ir-
reversible after esophageal remodeling in patients with EoE. 
These findings should be validated with further prospective, 
multi-center studies with long-term follow-up.
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